Clinical trials: DENGUE
Zika Virus Infection
Safety and Immunogenicity of BBV121
To evaluate the safety, tolerability, and immunogenicity of two-doses of three-sequentially escalating cohort (2.5 µg, 5 µg and 10 µg) of BBV121 (purified inactivated adsorbed Zika virus vaccine) compared with Placebo (Alum).
- Trial name
- Zika (NCT04478656)
- Testing
- BBV121
- Where
- India
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Bharat Biotech International Limited
Dengue
Immunogenicity and Safety of Tetravalent Dengue Vaccine (TDV) in Adolescents in Non-Endemic Area(s)
The purpose of this study was to describe the neutralizing antibody response against each dengue serotype at 1 month post second dose of TDV or placebo in dengue-naive adolescent participants.
- Trial name
- NCT03341637
- Testing
- Tetravalent Dengue Vaccine (TDV)
- Where
- 5 sites in Mexico
- Volunteers
- 400 people, healthy volunteers welcome
- Sponsor
- Takeda
Dengue
Evaluating the Safety and Immune Response to Two Admixtures of a Tetravalent Dengue Virus Vaccine
Dengue viruses can cause dengue fever and other serious health conditions, primarily affecting people living in tropical regions of the world.
- Trial name
- NCT01506570
- Testing
- TetraVax-DV Vaccine - Admixture TV003, TetraVax-DV Vaccine - Admixture TV005
- Where
- 3 sites in United States
- Volunteers
- 58 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Dengue Shock Syndrome, Dengue Hemorrhagic Fever
Safety of and Immune Response to DEN4 Vaccine Component Candidate for Dengue Virus
Infection with dengue viruses is one of the leading causes of hospitalization and death in children in several tropical Asian counties.
- Trial name
- NCT00919178
- Testing
- DEN4 Vaccine Candidate
- Where
- 2 sites in United States
- Volunteers
- 70 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Dengue
Procleix® Dengue Virus Assay Testing of Individual Donor Samples From Puerto Rican Blood Donors - American Red Cross
The objective of this study is to test individual donor samples (IDSs) with the investigational Dengue Assay on the TIGRIS System and to further characterize the Dengue Assay in the clinical setting.
- Trial name
- NCT01656174
- Testing
- Procleix Dengue Virus Assay
- Where
- 2 sites in United States
- Volunteers
- 35,035 people, healthy volunteers welcome
- Sponsor
- Gen-Probe, Incorporated
Dengue Fever
Diagnosis and Characterization of Dengue Fever in Children
Dengue virus is an arbovirus transmitted by mosquitoes which causes significant morbidity and mortality among children in tropical regions, especially in resource limited countries.
- Trial name
- NCT00946218
- Where
- 2 sites in United States, El Salvador
- Volunteers
- 258 people
- Sponsor
- St. Jude Children's Research Hospital
Dengue Fever, Fever
Prospective Surveillance of Febrile Illness for Dengue-Endemic Areas in Asia
The purpose of this study is to detect acute febrile episodes and dengue infection in five Asian countries, to assess dengue seroprevalence, and to assess surveillance infrastructure at investigational sites in anticipation of a…
- Trial name
- NCT01218906
- Where
- 11 sites in Indonesia, Malaysia and 3 more
- Volunteers
- 1,500 people, healthy volunteers welcome
- Sponsor
- Sanofi
Dengue Fever
Safety Study of a Vaccine (DENV-1 PIV) to Prevent Dengue Disease
This is a phase 1 study to evaluate the safety of a vaccine (DENV-1 PIV) for the prevention of dengue fever.
- Trial name
- DENV-1 PIV (NCT01502735)
- Testing
- DENV-1 PIV, 2.5 µg, DENV-1 PIV, 5 µg
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- U.S. Army Medical Research and Development Command
Dengue, Severe Dengue
Dengue Effectiveness Study in the Philippines
This is an observational study that aims to determine the effectiveness of a tetravalent dengue vaccine (CYD-TDV) when given through a community-based immunization program against hospitalized and /or severe virologically…
- Conditions
- Dengue, Severe Dengue, Virologically Confirmed Dengue
- Trial name
- NCT03803618
- Where
- 4 sites in Philippines
- Volunteers
- 2,081 people, healthy volunteers welcome
- Sponsor
- University of the Philippines
Viral Infection
Study to Determine the Safety, Tolerability and Pharmacokinetics of UV-4B Solution Administered Orally in Healthy Subjects
The objective is to evaluate the safety and tolerability of a single-ascending oral dose of UV-4B in healthy subjects and to determine pharmacokinetic parameters describing absorption and elimination following a single dose of…
- Trial name
- UV (NCT02061358)
- Testing
- UV-4B 3 mg, UV-4B 10 mg, UV-4B 30 mg
- Where
- United States
- Volunteers
- 64 people, healthy volunteers welcome
- Sponsor
- Emergent BioSolutions
Dengue
Evaluating the Safety and Immune Response to a Dengue Virus Vaccine in Healthy Adults
Dengue viruses can cause dengue fever and other more serious illnesses. The purpose of this study is to evaluate the safety and immune response to a dengue virus vaccine.
- Trial name
- NCT01931176
- Testing
- rDEN2Δ30-7169 vaccine
- Where
- United States
- Volunteers
- 14 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Dengue
Demonstration of an Electronic Clinical Decision Support Module for Dengue in Burkina Faso
The Integrated Management of Childhood Illness (IMCI) guideline has been implemented in Burkina Faso and is used across primary health facilities to assess children under the age of 5 years.
- Trial name
- NCT04582474
- Testing
- Dengue module and rapid diagnostic tests
- Where
- 2 sites in Burkina Faso
- Volunteers
- 335 people
- Sponsor
- Foundation for Innovative New Diagnostics, Switzerland
Dengue
Serological Study of Dengue and Characterization of Immune Response in Ten Endemic and Non-Endemic Cities in Mexico
Background: Dengue continues to be a high priority disease for public health in tropical and subtropical countries, where vector control measures have not had the expected impact on transmission.
- Trial name
- NCT04947111
- Testing
- Estimate the distribution of antibodies by serotype by Dengue virus in areas of low and high incidence of dengue
- Where
- Mexico
- Volunteers
- 1,960 people, healthy volunteers welcome
- Sponsor
- Mexican Society of Public Health
Dengue
Efficacy and Safety of Carica Papaya in Dengue Fever: A Randomised Clinical Trial
This will be a placebo-controlled, multicenter-randomized prospective study of CPLE (Carica papaya leaf extract) tabs in dengue patients (WHO-Group A, B).
- Trial name
- NCT06121934
- Testing
- Carica Papaya Leaf Extract
- Where
- Bangladesh
- Volunteers
- 250 people
- Sponsor
- Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh
Knowledge, Attitudes, Practice
Effectiveness of iDEAL in Improving the Knowledge, Attitude, Practice, Environmental Cleanliness Index and Dengue Index
Background Dengue is a mosquito-borne viral disease caused by four distinct but closely related dengue virus (DENV). The incidence of dengue has grown dramatically worldwide in recent decades, with cases reported to WHO increased…
- Trial name
- iDEAL (NCT05863026)
- Testing
- THEORY BASED INTEGRATED DENGUE EDUCATION AND LEARNING MODULE (iDEAL)
- Where
- Malaysia
- Volunteers
- 1,600 people, healthy volunteers welcome
- Sponsor
- Universiti Putra Malaysia
West Nile Fever Encephalitis
Safety of and Immune Response to a West Nile Virus Vaccine (WN/DEN4-3'delta30) in Healthy Adults
West Nile (WN) virus infection is an emerging disease; WN infection may lead to paralysis, coma, and death. The purpose of this study is to test the safety of and immune response to a WN vaccine in healthy adults.
- Trial name
- NCT00094718
- Testing
- WN/DEN4-3'delta30
- Where
- 2 sites in United States
- Volunteers
- 56 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Dengue, Dengue Fever
Immunologic Mechanisms of Immune Interference and/or Cross-Neutralizing Immunity After CYD Tetravalent Dengue Vaccine
The aim of the study was to evaluate a compressed dosing schedule and the immunologic effects of co-administration of a CYD dengue vaccine with a licensed flavivirus (FV) with Japanese encephalitis (JE) vaccine.
- Conditions
- Dengue, Dengue Fever, Dengue Hemorrhagic Fever
- Trial name
- NCT01943825
- Testing
- CYD Dengue Vaccine, Japanese Encephalitis Vaccine
- Where
- United States
- Volunteers
- 90 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Dengue Hemorrhagic
Resuscitation With Albumin 5% in Dengue Haemorrhagic Fever
Endothelial cell had important role in plasma leakage process. Plasma leakage occurs due to increased vascular permeability caused by disruption of endothelial glycocalyx showed by increased syndecan-1 level in serum.
- Trial name
- NCT04076254
- Testing
- Albumins, Fluid
- Where
- Indonesia
- Volunteers
- 84 people
- Sponsor
- Universitas Indonesia
Dengue Fever
Safety of and Immune Response to a Dengue Virus Vaccine (rDEN4delta30-200,201) in Healthy Adults
Dengue fever, which is caused by dengue viruses, is a major health problem in tropical and subtropical regions of the world. The purpose of this study is to test the safety of and immune response to a new dengue virus vaccine in…
- Trial name
- NCT00270699
- Testing
- rDEN4delta30-200,201
- Where
- United States
- Volunteers
- 56 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Dengue
TDENV PIV and LAV Dengue Prime-boost Strategy Using AS03B Adjuvant
The potential synergistic effect of administering 2 dengue vaccine candidates that were previously shown to be safe and immunogenic in humans will be evaluated in this study.
- Trial name
- NCT03110952
- Testing
- TDENV-PIV, TDENV-F17
- Where
- United States
- Volunteers
- healthy volunteers welcome
- Sponsor
- U.S. Army Medical Research and Development Command